The main participants in the financing round are NeuroSearch, SLS Venture, Dansk Kapitalanlæg, Dansk Erhvervsinvestering and Vækstfonden.
Sophion was founded in 2000 as a spin-out from NeuroSearch where IP and know-how within the technology of high throughput screening of ion-channel modulators was transferred to the company. This technology known as “patch clamping” is vital within ion-channel based drug discovery. Patch clamping generates highly detailed information about ion-channel activity in living cells, but is traditionally very time consuming and requires highly educated operators.
Sophion recently completed the development of QPatch 16 and the system will be externally tested by NeuroSearch and by an international pharmaceutical company over the next months. The first commercial units are scheduled for shipping in second quarter 2004.
QPatch 16 is based on a unique combination of cell biology, microtechnology and microfluidics enabling automatic positioning and sealing of single cells as well as electrical characterization of their ion channel activity. 16 simultaneous experiments are conducted on a consumable measurement plate increasing the throughput up to a factor 100 compared to current manual methods.
Fully implemented, the technology will enable the discovery and development of new ion-channel based drugs and potentially provide new and better drugs faster.
Further information: www.sophion.dk
Contact:
Torsten Freltoft, CEO +45 4460 8811
Frank Henrichsen, VP Sales & Marketing +45 4460 8820
page top
Join our mailinglist